During the recent TPP furore, Labour made much of the threat to Pharmac from American drug multinationals. And now, just weeks after signing the TPP, the greatest threat to our independent drug buyer comes from Labour itself. …
In 2009 we wrote Health Cheque – the truth we should all know about New Zealand’s public health system. This found that Pharmac was the envy of every health system in the world. The follow up Prescription for Change found that if anything the Pharmac approach – getting the politicians out of decision making and leaving it to the experts – should be expanded across the rest of the health sector.
Instead it is once again under threat from meddling politicians. …
It seems that every three elections Pharmac becomes an issue. Last time around it was the National Party in 2008 arguing for Herceptin to be funded. Late last year Health Minister Jonathan Coleman admitted that Prime Minister John Key had “made a mistake” over his promise to fund Herceptin. Of course back then National were in Opposition and wanted to win an election. This ensured Mr Key was impervious to the uproar over his Herceptin hypocrisy at the time. He was not making a mistake at all, it was pure politicking that led to his call to undermine Pharmac at that time.
Now it’s Andrew Little’s turn. Despite the Helen Clark Government holding the line on Herceptin in 2008, Mr Little is cynical enough to accuse Mr Key of being cycnical and in the same sentence then say that this melanoma drug Keytruda should be funded by Pharmac. He acknowledges that Pharmac is an independent body, but says that sometimes it needs to be overridden. Apparently it’s okay for the pot to call the kettle black.
When the heat comes on in politics, principles go out the window. – we need to all remember that when it comes to assessing the validity of politicians’ utterances.
Both National and Labour have erred here.
The focus by the media has gone on the effectiveness of Keytruda, using some anecdotes of early successes. Pharmac has responded that it is way too early to consider the long term efficacy of Keytruda and they will announce when they think they have enough data to make an informed decision.
The other side of the coin of course is cost. These drugs are hugely expensive, and so to meet Pharmac’s value of money criteria they need to be outstandingly effective. That is the harsh reality that melanoma sufferers – along with several other categories of cancer patients have to face. Pharmac has limited funds (now that is the role of the political process), and its job is to get the most health benefit from that as possible.
We need to bear in mind that Pharmac are negotiating with profit seeking companies here. The more politicians meddle with that, the more the drug companies will milk it. In other words if we keep throwing money at this problem, they will keep putting their prices up.
Mr Little argued that there could be a separate fund for temporarily funding experimental new drugs while we work out if they are effective. This is a ridiculous idea. When in the history of government has it ever been able to stop funding a drug once they start? He also points out that other countries are funding Keytruda. Yes – and a host of other drugs besides, different countries have different funding models.
Keytruda is the first of many such next generation drugs that help people’s immune system to fight cancer – so their own immune system does the heavy lifting in getting rid of the cancer. All these drugs are going to be expensive, and the technology will take a while to be proven. We have to let Pharmac do its job, otherwise we will be having this conversation every few months, politicians will keep running interference in order to covet special interest votes, and our drugs bill will explode.
Unless taxpayers are happy to fund every drug on earth at any price, politicians need to get back in their cages, let Pharmac do its job of allocating the budget. The only political decision should be the size of their budget.
A rare post in which I agree with everything Gareth Morgan says.